Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Lorenzo Trippa, Ph.D.

Title
Institution
Department
Address
Profile Picture

Overview
I am interested in the development of adaptive clinical trial designs. My research includes the study of algorithms and methodologies for the analysis of data generated by adaptive trials. I am also particularly interested in Bayesian nonparametrics, a great source of modeling opportunity in biomedical applications as well as, both computational and theoretical problems.

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Kotecha G, Ventz S, Trippa L. Prospectively shared control data across concurrent randomised clinical trials. Eur J Cancer. 2022 Dec 12; 181:18-20. PMID: 36621117.
    Citations:    Fields:    
  2. Sklavenitis-Pistofidis R, Aranha MP, Redd RA, Baginska J, Haradhvala NJ, Hallisey M, Dutta AK, Savell A, Varmeh S, Heilpern-Mallory D, Ujwary S, Zavidij O, Aguet F, Su NK, Lightbody ED, Bustoros M, Tahri S, Mouhieddine TH, Wu T, Flechon L, Anand S, Rosenblatt JM, Zonder J, Vredenburgh JJ, Boruchov A, Bhutani M, Usmani SZ, Matous J, Yee AJ, Jakubowiak A, Laubach J, Manier S, Nadeem O, Richardson P, Badros AZ, Mateos MV, Trippa L, Getz G, Ghobrial IM. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell. 2022 11 14; 40(11):1358-1373.e8. PMID: 36379208.
    Citations: 1     Fields:    Translation:Humans
  3. Ventz S, Khozin S, Louv B, Sands J, Wen PY, Rahman R, Comment L, Alexander BM, Trippa L. The design and evaluation of hybrid controlled trials that leverage external data and randomization. Nat Commun. 2022 10 02; 13(1):5783. PMID: 36184621; PMCID: PMC9527257.
    Citations: 1     Fields:    Translation:Humans
  4. Shyr C, Blackford AL, Huang T, Ke J, Ouardaoui N, Trippa L, Syngal S, Ukaegbu C, Uno H, Nafa K, Stadler ZK, Offit K, Amos CI, Lynch PM, Chen S, Giardiello FM, Buchanan DD, Hopper JL, Jenkins MA, Southey MC, Win AK, Figueiredo JC, Braun D, Parmigiani G. A validation of models for prediction of pathogenic variants in mismatch repair genes. Genet Med. 2022 10; 24(10):2155-2166. PMID: 35997715.
    Citations:    Fields:    Translation:HumansCells
  5. Saraf A, Trippa L, Rahman R. Novel Clinical Trial Designs in Neuro-Oncology. Neurotherapeutics. 2022 10; 19(6):1844-1854. PMID: 35969361; PMCID: PMC9723049.
    Citations: 1     Fields:    Translation:Humans
  6. Lauffenburger JC, Choudhry NK, Russo M, Glynn RJ, Ventz S, Trippa L. Designing and conducting adaptive trials to evaluate interventions in health services and implementation research: practical considerations. BMJ Med. 2022; 1(1). PMID: 36386444; PMCID: PMC9650931.
    Citations:    
  7. Bustoros M, Anand S, Sklavenitis-Pistofidis R, Redd R, Boyle EM, Zhitomirsky B, Dunford AJ, Tai YT, Chavda SJ, Boehner C, Neuse CJ, Rahmat M, Dutta A, Casneuf T, Verona R, Kastritis E, Trippa L, Stewart C, Walker BA, Davies FE, Dimopoulos MA, Bergsagel PL, Yong K, Morgan GJ, Aguet F, Getz G, Ghobrial IM. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. Nat Commun. 2022 06 15; 13(1):3449. PMID: 35705541; PMCID: PMC9200804.
    Citations:    Fields:    Translation:Humans
  8. Trippa L, Bacallado S. Empirical Evaluations of Clinical Trial Designs. JAMA Netw Open. 2022 05 02; 5(5):e2211620. PMID: 35544143.
    Citations:    Fields:    Translation:Humans
  9. Tahri S, Mouhieddine TH, Redd R, Lampe L, Nilsson KI, El-Khoury H, Su NK, Nassar AH, Adib E, Bindra G, Abou Alaiwi S, Trippa L, Steensma DP, Castillo JJ, Treon SP, Ghobrial IM, Sperling AS. Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia. Blood Adv. 2022 04 12; 6(7):2230-2235. PMID: 34847227; PMCID: PMC9006277.
    Citations:    Fields:    Translation:Humans
  10. El-Khoury H, Lee DJ, Alberge JB, Redd R, Cea-Curry CJ, Perry J, Barr H, Murphy C, Sakrikar D, Barnidge D, Bustoros M, Leblebjian H, Cowan A, Davis MI, Amstutz J, Boehner CJ, Lightbody ED, Sklavenitis-Pistofidis R, Perkins MC, Harding S, Mo CC, Kapoor P, Mikhael J, Borrello IM, Fonseca R, Weiss ST, Karlson E, Trippa L, Rebbeck TR, Getz G, Marinac CR, Ghobrial IM. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. Lancet Haematol. 2022 May; 9(5):e340-e349. PMID: 35344689; PMCID: PMC9067621.
    Citations:    Fields:    Translation:Humans
  11. Thomas EG, Braun D, Kioumourtzoglou MA, Trippa L, Wasfy JH, Dominici F. A Bayesian Multi-Outcome Analysis of Fine Particulate Matter and Cardiorespiratory Hospitalizations. Epidemiology. 2022 03 01; 33(2):176-184. PMID: 35104259; PMCID: PMC8852365.
    Citations:    Fields:    Translation:HumansPHPublic Health
  12. Barroso-Sousa R, Tarantino P, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy KJ, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I, Tolaney SM. Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. NPJ Breast Cancer. 2022 Feb 16; 8(1):18. PMID: 35173164; PMCID: PMC8850608.
    Citations:    
  13. Ventz S, Comment L, Louv B, Rahman R, Wen PY, Alexander BM, Trippa L. The use of external control data for predictions and futility interim analyses in clinical trials. Neuro Oncol. 2022 02 01; 24(2):247-256. PMID: 34106270; PMCID: PMC8804894.
    Citations: 2     Fields:    Translation:Humans
  14. Konishi Y, Sklavenitis-Pistofidis R, Yue H, Ferrari F, Redd RA, Lightbody ED, Russo M, Perry J, Horowitz E, Justis AV, Shayegh NA, Savell A, Prescott J, Varmeh S, Nowak RP, Hamilton M, Auclair D, Marinac CR, Trippa L, Fischer ES, Ghobrial IM. Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia. Cancer Cell. 2022 01 10; 40(1):6-8. PMID: 34895486; PMCID: PMC8654583.
    Citations: 3     Fields:    Translation:HumansCells
  15. Russo M, Ventz S, Wang V, Trippa L. Inference in response-adaptive clinical trials when the enrolled population varies over time. Biometrics. 2021 Oct 21. PMID: 34674228; PMCID: PMC9021332.
    Citations:    Fields:    
  16. Rahman R, Ventz S, McDunn J, Louv B, Reyes-Rivera I, Polley MC, Merchant F, Abrey LE, Allen JE, Aguilar LK, Aguilar-Cordova E, Arons D, Tanner K, Bagley S, Khasraw M, Cloughesy T, Wen PY, Alexander BM, Trippa L. Leveraging external data in the design and analysis of clinical trials in neuro-oncology. Lancet Oncol. 2021 10; 22(10):e456-e465. PMID: 34592195; PMCID: PMC8893120.
    Citations:    Fields:    Translation:Humans
  17. Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, Bonnet M, Chang E, Cloez S, Coit JM, Cox V, de Jong BC, Delifer C, Do JM, Tozzi DDS, Ducher V, Ferlazzo G, Gouillou M, Khan A, Khan U, Lachenal N, LaHood AN, Lecca L, Mazmanian M, McIlleron H, Moschioni M, O'Brien K, Okunbor O, Oyewusi L, Panda S, Patil SB, Phillips PPJ, Pichon L, Rupasinghe P, Rich ML, Saluhuddin N, Seung KJ, Tamirat M, Trippa L, Cellamare M, Velásquez GE, Wasserman S, Zimetbaum PJ, Varaine F, Mitnick CD. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials. 2021 Sep 25; 22(1):651. PMID: 34563240.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  18. Barroso-Sousa R, Vaz-Luis I, Di Meglio A, Hu J, Li T, Rees R, Sinclair N, Milisits L, Leone JP, Constantine M, Faggen M, Briccetti F, Block C, Partridge A, Burstein H, Waks AG, Tayob N, Trippa L, Tolaney SM, Hassett MJ, Winer EP, Lin NU. Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. Oncologist. 2021 11; 26(11):927-933. PMID: 34472667.
    Citations:    Fields:    Translation:Humans
  19. Ventz S, Mazumder R, Trippa L. Integration of survival data from multiple studies. Biometrics. 2022 12; 78(4):1365-1376. PMID: 34190337.
    Citations:    Fields:    
  20. Barroso-Sousa R, Keenan TE, Li T, Tayob N, Trippa L, Pastorello RG, Richardson Iii ET, Dillon D, Amoozgar Z, Overmoyer B, Schnitt SJ, Winer EP, Mittendorf EA, Van Allen E, Duda DG, Tolaney SM. Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. NPJ Breast Cancer. 2021 Aug 25; 7(1):110. PMID: 34433812.
    Citations: 1     
  21. Fell G, Redd RA, Vanderbeek AM, Rahman R, Louv B, McDunn J, Arfè A, Alexander BM, Ventz S, Trippa L. KMDATA: a curated database of reconstructed individual patient-level data from 153 oncology clinical trials. Database (Oxford). 2021 06 26; 2021. PMID: 34169314.
    Citations: 1     Fields:    Translation:Humans
  22. Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol. 2021 07 20; 39(21):2375-2385. PMID: 34077270.
    Citations: 14     Fields:    Translation:Humans
  23. Filho OM, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA, Abramson VG, Arteaga CL, Spring LM, Waks AG, Wrabel E, DeMeo MK, Bardia A, Dell'Orto P, Russo L, King TA, Polyak K, Michor F, Winer EP, Krop IE. Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Discov. 2021 10; 11(10):2474-2487. PMID: 33941592; PMCID: PMC8598376.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  24. Tabrizi S, Trippa L, Cagney D, Aizer AA, Tanguturi S, Ventz S, Fell G, Bellon JR, Mamon H, Nguyen PL, D'Amico AV, Haas-Kogan D, Alexander BM, Rahman R. Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials. JAMA Netw Open. 2021 03 01; 4(3):e213304. PMID: 33779742.
    Citations:    Fields:    Translation:HumansPHPublic Health
  25. Ventz S, Bacallado S, Rahman R, Tolaney S, Schoenfeld JD, Alexander BM, Trippa L. The effects of releasing early results from ongoing clinical trials. Nat Commun. 2021 02 05; 12(1):801. PMID: 33547324.
    Citations: 1     Fields:    Translation:Humans
  26. Lauffenburger JC, Isaac T, Trippa L, Keller P, Robertson T, Glynn RJ, Sequist TD, Kim DH, Fontanet CP, Castonguay EWB, Haff N, Barlev RA, Mahesri M, Gopalakrishnan C, Choudhry NK. Rationale and design of the Novel Uses of adaptive Designs to Guide provider Engagement in Electronic Health Records (NUDGE-EHR) pragmatic adaptive randomized trial: a trial protocol. Implement Sci. 2021 01 07; 16(1):9. PMID: 33413494; PMCID: PMC7792313.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  27. Schoenfeld JD, Fell G, Haddad RI, Trippa L. Reply to "Keynote 48: Is it really for everyone?" Oral Oncol. 2021 04; 115:105108. PMID: 33277202.
    Citations:    Fields:    
  28. Arfè A, Fell G, Alexander B, Awad MM, Rodig SJ, Trippa L, Schoenfeld JD. Meta-Analysis of PD-L1 Expression As a Predictor of Survival After Checkpoint Blockade. JCO Precis Oncol. 2020 Nov; 4:1196-1206. PMID: 35050777.
    Citations:    Fields:    
  29. Tolaney SM, Barroso-Sousa R, Keenan T, Li T, Trippa L, Vaz-Luis I, Wulf G, Spring L, Sinclair NF, Andrews C, Pittenger J, Richardson ET, Dillon D, Lin NU, Overmoyer B, Partridge AH, Van Allen E, Mittendorf EA, Winer EP, Krop IE. Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1598-1605. PMID: 32880602.
    Citations: 24     Fields:    Translation:HumansCTClinical Trials
  30. Losk K, Freedman RA, Laws A, Kantor O, Mittendorf EA, Tan-Wasielewski Z, Trippa L, Lin NU, Winer EP, King TA. Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. Breast Cancer Res Treat. 2021 Jan; 185(1):215-227. PMID: 32939592.
    Citations: 5     Fields:    Translation:Humans
  31. Mayer EL, Abramson V, Jankowitz R, Falkson C, Marcom PK, Traina T, Carey L, Rimawi M, Specht J, Miller K, Stearns V, Tung N, Perou C, Richardson AL, Componeschi K, Trippa L, Tan-Wasielewski Z, Timms K, Krop I, Wolff AC, Winer EP. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. Ann Oncol. 2020 11; 31(11):1518-1525. PMID: 32798689; PMCID: PMC8437015.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  32. Arfè A, Ventz S, Trippa L. Shared and Usable Data From Phase 1 Oncology Trials-An Unmet Need. JAMA Oncol. 2020 07 01; 6(7):980-981. PMID: 32496530.
    Citations: 4     Fields:    Translation:Humans
  33. Arfè A, Alexander B, Trippa L. Optimality of testing procedures for survival data in the nonproportional hazards setting. Biometrics. 2021 06; 77(2):587-598. PMID: 32535892.
    Citations: 4     Fields:    
  34. Mouhieddine TH, Sperling AS, Redd R, Park J, Leventhal M, Gibson CJ, Manier S, Nassar AH, Capelletti M, Huynh D, Bustoros M, Sklavenitis-Pistofidis R, Tahri S, Hornburg K, Dumke H, Itani MM, Boehner CJ, Liu CJ, AlDubayan SH, Reardon B, Van Allen EM, Keats JJ, Stewart C, Mehr S, Auclair D, Schlossman RL, Munshi NC, Anderson KC, Steensma DP, Laubach JP, Richardson PG, Ritz J, Ebert BL, Soiffer RJ, Trippa L, Getz G, Neuberg DS, Ghobrial IM. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; 11(1):2996. PMID: 32533060; PMCID: PMC7293239.
    Citations: 24     Fields:    Translation:Humans
  35. Metzger Filho O, Leone JP, Li T, Tan-Wasielewski Z, Trippa L, Barry WT, Younger J, Lawler E, Walker L, Freedman RA, Tolaney SM, Krop I, Winer EP, Lin NU. Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases. Ann Oncol. 2020 09; 31(9):1231-1239. PMID: 32461105.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  36. Bustoros M, Sklavenitis-Pistofidis R, Park J, Redd R, Zhitomirsky B, Dunford AJ, Salem K, Tai YT, Anand S, Mouhieddine TH, Chavda SJ, Boehner C, Elagina L, Neuse CJ, Cha J, Rahmat M, Taylor-Weiner A, Van Allen E, Kumar S, Kastritis E, Leshchiner I, Morgan EA, Laubach J, Casneuf T, Richardson P, Munshi NC, Anderson KC, Trippa L, Aguet F, Stewart C, Dimopoulos MA, Yong K, Bergsagel PL, Manier S, Getz G, Ghobrial IM. Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020 07 20; 38(21):2380-2389. PMID: 32442065; PMCID: PMC7367550.
    Citations: 37     Fields:    Translation:Humans
  37. Rahman R, Trippa L, Alden S, Fell G, Abbasi T, Mundkur Y, Singh NK, Talawdekar A, Husain Z, Vali S, Ligon KL, Wen PY, Alexander BM. Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide. Int J Radiat Oncol Biol Phys. 2020 11 01; 108(3):716-724. PMID: 32417407.
    Citations: 1     Fields:    Translation:Humans
  38. Schoenfeld JD, Fell G, Haddad RI, Trippa L. Keynote 48: Is it really for everyone? Oral Oncol. 2020 06; 105:104762. PMID: 32381470.
    Citations: 1     Fields:    Translation:Humans
  39. Tabrizi S, Trippa L, Cagney D, Tanguturi S, Ventz S, Fell G, Wen PY, Alexander BM, Rahman R. A Quantitative Framework for Modeling COVID-19 Risk During Adjuvant Therapy Using Published Randomized Trials of Glioblastoma in the Elderly. Neuro Oncol. 2020 Apr 27. PMID: 32339235.
    Citations: 7     Fields:    
  40. Vaz-Luis I, Barroso-Sousa R, Di Meglio A, Hu J, Rees R, Sinclair N, Milisits L, Leone JP, Constantine M, Faggen M, Briccetti F, Block C, O'Neil K, Partridge A, Burstein H, Waks AG, Trippa L, Tolaney SM, Hassett M, Winer EP, Lin NU. Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study. J Clin Oncol. 2020 07 20; 38(21):2390-2397. PMID: 32330102.
    Citations: 3     Fields:    Translation:Humans
  41. Parsons HA, Rhoades J, Reed SC, Gydush G, Ram P, Exman P, Xiong K, Lo CC, Li T, Fleharty M, Kirkner GJ, Rotem D, Cohen O, Yu F, Fitarelli-Kiehl M, Leong KW, Hughes ME, Rosenberg SM, Collins LC, Miller KD, Blumenstiel B, Trippa L, Cibulskis C, Neuberg DS, DeFelice M, Freeman SS, Lennon NJ, Wagle N, Ha G, Stover DG, Choudhury AD, Getz G, Winer EP, Meyerson M, Lin NU, Krop I, Love JC, Makrigiorgos GM, Partridge AH, Mayer EL, Golub TR, Adalsteinsson VA. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clin Cancer Res. 2020 06 01; 26(11):2556-2564. PMID: 32170028.
    Citations: 28     Fields:    Translation:Humans
  42. Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, Smith BL, Alexander B, Moy B, Isakoff SJ, Parmigiani G, Trippa L, Bardia A. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res. 2020 06 15; 26(12):2838-2848. PMID: 32046998.
    Citations: 91     Fields:    Translation:Humans
  43. Barroso-Sousa R, Krop IE, Trippa L, Tan-Wasielewski Z, Li T, Osmani W, Andrews C, Dillon D, Richardson ET, Pastorello RG, Winer EP, Mittendorf EA, Bellon JR, Schoenfeld JD, Tolaney SM. A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. Clin Breast Cancer. 2020 06; 20(3):238-245. PMID: 32113750.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  44. Exman P, Garrido-Castro AC, Hughes ME, Freedman RA, Li T, Trippa L, Bychkovsky BL, Barroso-Sousa R, Di Lascio S, Mackichan C, Lloyd MR, Krevalin M, Cerami E, Merrill MS, Santiago R, Crowley L, Kuhnly N, Files J, Lindeman NI, MacConaill LE, Kumari P, Tolaney SM, Krop IE, Bose R, Johnson BE, Ma CX, Dillon DA, Winer EP, Wagle N, Lin NU. Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. JCO Precis Oncol. 2019; 3. PMID: 32923853.
    Citations: 1     Fields:    
  45. Vanderbeek AM, Ventz S, Rahman R, Fell G, Cloughesy TF, Wen PY, Trippa L, Alexander BM. To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs. Neuro Oncol. 2019 10 09; 21(10):1239-1249. PMID: 31155679.
    Citations: 5     Fields:    Translation:Humans
  46. Ghobrial IM, Liu CJ, Zavidij O, Azab AK, Baz R, Laubach JP, Mishima Y, Armand P, Munshi NC, Basile F, Constantine M, Vredenburgh J, Boruchov A, Crilley P, Henrick PM, Hornburg KTV, Leblebjian H, Chuma S, Reyes K, Noonan K, Warren D, Schlossman R, Paba-Prada C, Anderson KC, Weller E, Trippa L, Shain K, Richardson PG. Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Am J Hematol. 2019 11; 94(11):1244-1253. PMID: 31456261.
    Citations: 20     Fields:    Translation:HumansCellsCTClinical Trials
  47. Leone JP, Duda DG, Hu J, Barry WT, Trippa L, Gerstner ER, Jain RK, Tan S, Lawler E, Winer EP, Lin NU, Tolaney SM. A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Res Treat. 2020 Jan; 179(1):113-123. PMID: 31541381.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  48. Ventz S, Trippa L, Schoenfeld JD. Lessons Learned from Deescalation Trials in Favorable Risk HPV-Associated Squamous Cell Head and Neck Cancer-A Perspective on Future Trial Designs. Clin Cancer Res. 2019 12 15; 25(24):7281-7286. PMID: 31527164.
    Citations: 8     Fields:    Translation:HumansCells
  49. Rahman R, Fell G, Ventz S, Arfé A, Vanderbeek AM, Trippa L, Alexander BM. Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications. Clin Cancer Res. 2019 11 01; 25(21):6339-6345. PMID: 31345838.
    Citations: 12     Fields:    Translation:Humans
  50. Zhang Y, Trippa L, Parmigiani G. Frequentist operating characteristics of Bayesian optimal designs via simulation. Stat Med. 2019 09 20; 38(21):4026-4039. PMID: 31215685.
    Citations: 1     Fields:    Translation:Humans
  51. Ventz S, Lai A, Cloughesy TF, Wen PY, Trippa L, Alexander BM. Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data. Clin Cancer Res. 2019 08 15; 25(16):4993-5001. PMID: 31175098.
    Citations: 16     Fields:    Translation:Humans
  52. Rahman R, Ventz S, Fell G, Vanderbeek AM, Trippa L, Alexander BM. Divining responder populations from survival data. Ann Oncol. 2019 06 01; 30(6):1005-1013. PMID: 30860592.
    Citations: 3     Fields:    Translation:Humans
  53. Goel S, Pernas S, Tan-Wasielewski Z, Barry WT, Bardia A, Rees R, Andrews C, Tahara RK, Trippa L, Mayer EL, Winer EP, Spring LM, Tolaney SM. Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. Clin Breast Cancer. 2019 12; 19(6):399-404. PMID: 31235441.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  54. Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, Liu CJ, Kastritis E, Zanwar S, Fell G, Abeykoon JP, Hornburg K, Neuse CJ, Marinac CR, Liu D, Soiffer J, Gavriatopoulou M, Boehner C, Cappuccio JM, Dumke H, Reyes K, Soiffer RJ, Kyle RA, Treon SP, Castillo JJ, Dimopoulos MA, Ansell SM, Trippa L, Ghobrial IM. Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411. PMID: 30990729; PMCID: PMC6544461.
    Citations: 14     Fields:    Translation:Humans
  55. Alexander BM, Trippa L, Gaffey S, Arrillaga-Romany IC, Lee EQ, Rinne ML, Ahluwalia MS, Colman H, Fell G, Galanis E, de Groot J, Drappatz J, Lassman AB, Meredith DM, Nabors LB, Santagata S, Schiff D, Welch MR, Ligon KL, Wen PY. Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. JCO Precis Oncol. 2019; 3. PMID: 32914038; PMCID: PMC7448806.
    Citations: 19     Fields:    
  56. De Vito R, Bellio R, Trippa L, Parmigiani G. Multi-study factor analysis. Biometrics. 2019 03; 75(1):337-346. PMID: 30289163.
    Citations: 10     Fields:    Translation:Humans
  57. Gotmaker R, Barrington MJ, Reynolds J, Trippa L, Heritier S. Bayesian adaptive design: the future for regional anesthesia trials? Reg Anesth Pain Med. 2019 Mar 02. PMID: 30826745.
    Citations:    Fields:    
  58. Ventz S, Alexander BM, Trippa L. Bayesian Adaptive Randomization in Dose-Finding Trials. JAMA Netw Open. 2018 12 07; 1(8):e186075. PMID: 30646308.
    Citations:    Fields:    Translation:Humans
  59. Sklavenitis-Pistofidis R, Capelletti M, Liu CJ, Reidy M, Zavidij O, Huynh D, Henrick P, Savell A, Reyes K, Rivotto B, Bustoros M, Perilla-Glen A, Trippa L, Castillo JJ, Treon SP, Ghobrial IM. Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood. 2018 12 13; 132(24):2608-2612. PMID: 30366921; PMCID: PMC6293872.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  60. Vanderbeek AM, Rahman R, Fell G, Ventz S, Chen T, Redd R, Parmigiani G, Cloughesy TF, Wen PY, Trippa L, Alexander BM. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? Neuro Oncol. 2018 07 05; 20(8):1034-1043. PMID: 29518210; PMCID: PMC6280141.
    Citations: 35     Fields:    Translation:Humans
  61. Madsen T, Braun D, Peng G, Parmigiani G, Trippa L. Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data. Genet Epidemiol. 2018 09; 42(6):528-538. PMID: 29943416; PMCID: PMC6129424.
    Citations: 1     Fields:    Translation:Humans
  62. O'Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG, Wade PM, Paba-Prada CE, Ghobrial IM, Schlossman RL, Burke JN, Harrington CC, Lively KJ, Lyons HF, Munshi NC, Anderson KC, Trippa L, Richardson PG, Raje NS. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018 07; 182(2):222-230. PMID: 29740809; PMCID: PMC6074026.
    Citations: 42     Fields:    Translation:HumansCTClinical Trials
  63. Ventz S, Cellamare M, Parmigiani G, Trippa L. Adding experimental arms to platform clinical trials: randomization procedures and interim analyses. Biostatistics. 2018 04 01; 19(2):199-215. PMID: 29036330.
    Citations: 7     Fields:    Translation:Humans
  64. Alexander BM, Schoenfeld JD, Trippa L. Hazards of Hazard Ratios - Deviations from Model Assumptions in Immunotherapy. N Engl J Med. 2018 03 22; 378(12):1158-1159. PMID: 29562148.
    Citations: 23     Fields:    Translation:Humans
  65. Tanguturi SK, Trippa L, Ramkissoon SH, Pelton K, Knoff D, Sandak D, Lindeman NI, Ligon AH, Beroukhim R, Parmigiani G, Wen PY, Ligon KL, Alexander BM. Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. Neuro Oncol. 2017 Jul 01; 19(7):908-917. PMID: 28339723; PMCID: PMC5570228.
    Citations: 11     Fields:    Translation:HumansCells
  66. Ventz S, Alexander BM, Parmigiani G, Gelber RD, Trippa L. Designing Clinical Trials That Accept New Arms: An Example in Metastatic Breast Cancer. J Clin Oncol. 2017 Sep 20; 35(27):3160-3168. PMID: 28530853.
    Citations: 12     Fields:    Translation:Humans
  67. Friedman AA, Xia Y, Trippa L, Le LP, Igras V, Frederick DT, Wargo JA, Tanabe KK, Lawrence DP, Neuberg DS, Flaherty KT, Fisher DE. Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. Clin Cancer Res. 2017 Aug 15; 23(16):4680-4692. PMID: 28446504; PMCID: PMC5559310.
    Citations: 3     Fields:    Translation:HumansAnimals
  68. Ren B, Bacallado S, Favaro S, Holmes S, Trippa L. Bayesian Nonparametric Ordination for the Analysis of Microbial Communities. J Am Stat Assoc. 2017; 112(520):1430-1442. PMID: 29430070.
    Citations: 9     
  69. Ventz S, Barry WT, Parmigiani G, Trippa L. Bayesian response-adaptive designs for basket trials. Biometrics. 2017 09; 73(3):905-915. PMID: 28211944.
    Citations: 9     Fields:    Translation:Humans
  70. Manier S, Liu CJ, Avet-Loiseau H, Park J, Shi J, Campigotto F, Salem KZ, Huynh D, Glavey SV, Rivotto B, Sacco A, Roccaro AM, Bouyssou J, Minvielle S, Moreau P, Facon T, Leleu X, Weller E, Trippa L, Ghobrial IM. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood. 2017 04 27; 129(17):2429-2436. PMID: 28213378; PMCID: PMC5409448.
    Citations: 111     Fields:    Translation:HumansCells
  71. Trippa L, Alexander BM. Bayesian Baskets: A Novel Design for Biomarker-Based Clinical Trials. J Clin Oncol. 2017 Feb 20; 35(6):681-687. PMID: 28045624.
    Citations: 11     Fields:    Translation:Humans
  72. Cellamare M, Milstein M, Ventz S, Baudin E, Trippa L, Mitnick CD. Bayesian adaptive randomization in a clinical trial to identify new regimens for MDR-TB: the endTB trial. Int J Tuberc Lung Dis. 2016 12 01; 20(12):8-12. PMID: 28240566.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  73. Cellamare M, Ventz S, Baudin E, Mitnick CD, Trippa L. A Bayesian response-adaptive trial in tuberculosis: The endTB trial. Clin Trials. 2017 Feb; 14(1):17-28. PMID: 27559021.
    Citations: 11     Fields:    Translation:Humans
  74. Giecold G, Marco E, Garcia SP, Trippa L, Yuan GC. Robust lineage reconstruction from high-dimensional single-cell data. Nucleic Acids Res. 2016 08 19; 44(14):e122. PMID: 27207878; PMCID: PMC5001598.
    Citations: 13     Fields:    Translation:Animals
  75. Antonelli J, Trippa L, Haneuse S. Mitigating Bias in Generalized Linear Mixed Models: The Case for Bayesian Nonparametrics. Stat Sci. 2016 Feb; 31(1):80-95. PMID: 28979066.
    Citations: 3     
  76. Zhang Y, Trippa L, Parmigiani G. Optimal Bayesian adaptive trials when treatment efficacy depends on biomarkers. Biometrics. 2016 06; 72(2):414-21. PMID: 26575199.
    Citations: 1     Fields:    Translation:Humans
  77. Zhao L, Claggett B, Tian L, Uno H, Pfeffer MA, Solomon SD, Trippa L, Wei LJ. On the restricted mean survival time curve in survival analysis. Biometrics. 2016 Mar; 72(1):215-21. PMID: 26302239; PMCID: PMC5114026.
    Citations: 59     Fields:    Translation:Humans
  78. Bowden J, Trippa L. Unbiased estimation for response adaptive clinical trials. Stat Methods Med Res. 2017 Oct; 26(5):2376-2388. PMID: 26265771.
    Citations: 7     Fields:    Translation:Humans
  79. Alexander BM, Trippa L. Getting it first versus getting it right: weighing the value of and evidence for progression-free survival as a surrogate endpoint for overall survival in glioblastoma. Neuro Oncol. 2015 May; 17(5):765-6. PMID: 25846289; PMCID: PMC4482865.
    Citations: 1     Fields:    Translation:Humans
  80. Ramkissoon SH, Bi WL, Schumacher SE, Ramkissoon LA, Haidar S, Knoff D, Dubuc A, Brown L, Burns M, Cryan JB, Abedalthagafi M, Kang YJ, Schultz N, Reardon DA, Lee EQ, Rinne ML, Norden AD, Nayak L, Ruland S, Doherty LM, LaFrankie DC, Horvath M, Aizer AA, Russo A, Arvold ND, Claus EB, Al-Mefty O, Johnson MD, Golby AJ, Dunn IF, Chiocca EA, Trippa L, Santagata S, Folkerth RD, Kantoff P, Rollins BJ, Lindeman NI, Wen PY, Ligon AH, Beroukhim R, Alexander BM, Ligon KL. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1344-55. PMID: 25754088; PMCID: PMC4578577.
    Citations: 24     Fields:    Translation:Humans
  81. Trippa L, Wen PY, Parmigiani G, Berry DA, Alexander BM. Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials. Neuro Oncol. 2015 Aug; 17(8):1106-13. PMID: 25568226; PMCID: PMC4490868.
    Citations: 9     Fields:    Translation:Humans
  82. Marco E, Karp RL, Guo G, Robson P, Hart AH, Trippa L, Yuan GC. Bifurcation analysis of single-cell gene expression data reveals epigenetic landscape. Proc Natl Acad Sci U S A. 2014 Dec 30; 111(52):E5643-50. PMID: 25512504; PMCID: PMC4284553.
    Citations: 126     Fields:    Translation:HumansAnimalsCells
  83. Bourgeois EB, Johnson BN, McCoy AJ, Trippa L, Cohen AS, Marsh ED. A toolbox for spatiotemporal analysis of voltage-sensitive dye imaging data in brain slices. PLoS One. 2014; 9(9):e108686. PMID: 25259520.
    Citations: 7     Fields:    Translation:Animals
  84. Ventz S, Trippa L. Bayesian designs and the control of frequentist characteristics: a practical solution. Biometrics. 2015 Mar; 71(1):218-226. PMID: 25196832.
    Citations: 4     Fields:    
  85. Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro Oncol. 2015 Feb; 17(2):180-8. PMID: 25165194.
    Citations: 11     Fields:    Translation:Humans
  86. Xu Y, Trippa L, Müller P, Ji Y. Subgroup-Based Adaptive (SUBA) Designs for Multi-Arm Biomarker Trials. Stat Biosci. 2016 Jun; 8(1):159-180. PMID: 27617041; PMCID: PMC5014435.
    Citations: 10     
  87. Bernau C, Riester M, Boulesteix AL, Parmigiani G, Huttenhower C, Waldron L, Trippa L. Cross-study validation for the assessment of prediction algorithms. Bioinformatics. 2014 Jun 15; 30(12):i105-12. PMID: 24931973; PMCID: PMC4058929.
    Citations: 22     Fields:    Translation:Humans
  88. Alexander BM, Trippa L. Progression-free survival: too much risk, not enough reward? Neuro Oncol. 2014 May; 16(5):615-6. PMID: 24733851.
    Citations: 11     Fields:    Translation:Humans
  89. Riester M, Wei W, Waldron L, Culhane AC, Trippa L, Oliva E, Kim SH, Michor F, Huttenhower C, Parmigiani G, Birrer MJ. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst. 2014 Apr 03; 106(5). PMID: 24700803.
    Citations: 86     Fields:    Translation:HumansCells
  90. Wason JM, Trippa L. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials. Stat Med. 2014 Jun 15; 33(13):2206-21. PMID: 24421053.
    Citations: 38     Fields:    Translation:Humans
  91. Parmigiani G, Boca S, Ding J, Trippa L. Statistical tools and R software for cancer driver probabilities. Methods Mol Biol. 2014; 1101:113-34. PMID: 24233780.
    Citations:    Fields:    Translation:Humans
  92. Alexander BM, Wen PY, Trippa L, Reardon DA, Yung WK, Parmigiani G, Berry DA. Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2. Neuro Oncol. 2013 Aug; 15(8):972-8. PMID: 23857706.
    Citations: 14     Fields:    Translation:Humans
  93. Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM. Reply to B. Freidlin et al. J Clin Oncol. 2013 Mar 01; 31(7):970-1. PMID: 23565532.
    Citations: 2     Fields:    Translation:Humans
  94. Lee J, Quintana FA, Müller P, Trippa L. Defining Predictive Probability Functions for Species Sampling Models. Stat Sci. 2013; 28(2):209-222. PMID: 24368874.
    Citations: 8     
  95. Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol. 2012 Sep 10; 30(26):3258-63. PMID: 22649140.
    Citations: 35     Fields:    Translation:Humans
  96. Trippa L, Rosner GL, Müller P. Bayesian enrichment strategies for randomized discontinuation trials. Biometrics. 2012 Mar; 68(1):203-11. PMID: 21714780.
    Citations: 4     Fields:    Translation:Humans
  97. Trippa L, Müller P, Johnson W. The multivariate beta process and an extension of the Polya tree model. Biometrika. 2011 Mar; 98(1):17-34. PMID: 23956460.
    Citations: 5     Fields:    
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: SPH faculty should contact Faculty Affairs at facultyaffairshsph.harvard.edu).
Trippa's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (254)
Explore
_
Co-Authors (161)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.